Literature DB >> 23532499

Risk-based prostate cancer screening: who and how?

Allison S Glass1, K Clint Cary, Matthew R Cooperberg.   

Abstract

The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532499     DOI: 10.1007/s11934-013-0319-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  88 in total

1.  Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer.

Authors:  V Panebianco; A Sciarra; A Marcantonio; V Forte; T Biondi; A Laghi; C Catalano
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-08       Impact factor: 2.346

2.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Authors:  Mark H Kawachi; Robert R Bahnson; Michael Barry; J Erik Busby; Peter R Carroll; H Ballentine Carter; William J Catalona; Michael S Cookson; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Richard J Howe; Paul H Lange; Hans Lilja; Kevin R Loughlin; James Mohler; Judd Moul; Robert B Nadler; Stephen G Patterson; Joseph C Presti; Antoinette M Stroup; Robert Wake; John T Wei
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

3.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

4.  PSA screening among elderly men with limited life expectancies.

Authors:  Louise C Walter; Daniel Bertenthal; Karla Lindquist; Badrinath R Konety
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

5.  Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway.

Authors:  Richard M Martin; Lars Vatten; David Gunnell; Pål Romundstad; Tom I L Nilsen
Journal:  Cancer Causes Control       Date:  2009-03-11       Impact factor: 2.506

6.  Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

Authors:  Donna Pauler Ankerst; Jack Groskopf; John R Day; Amy Blase; Harry Rittenhouse; Brad H Pollock; Cathy Tangen; Dipen Parekh; Robin J Leach; Ian Thompson
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

7.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.

Authors:  Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer
Journal:  Cancer Causes Control       Date:  2007-11-20       Impact factor: 2.506

8.  Racial disparities in access to care for men in a public assistance program for prostate cancer.

Authors:  David C Miller; Lillian Gelberg; Lorna Kwan; Sevan Stepanian; Arlene Fink; Ronald M Andersen; Mark S Litwin
Journal:  J Community Health       Date:  2008-10

9.  Continued undertreatment of older men with localized prostate cancer.

Authors:  Kevin L Schwartz; Shabbir M H Alibhai; George Tomlinson; Gary Naglie; Murray D Krahn
Journal:  Urology       Date:  2003-11       Impact factor: 2.649

10.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

Authors:  Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja
Journal:  BMC Med       Date:  2008-07-08       Impact factor: 8.775

View more
  6 in total

1.  Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.

Authors:  Zheng Han; Yajuan Li; Sarah Roelle; Zhuxian Zhou; Yuchi Liu; Rob Sabatelle; Aidan DeSanto; Xin Yu; Hui Zhu; Cristina Magi-Galluzzi; Zheng-Rong Lu
Journal:  Bioconjug Chem       Date:  2017-03-09       Impact factor: 4.774

2.  Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI.

Authors:  Nadia R Ayat; Jing-Can Qin; Han Cheng; Sarah Roelle; Songqi Gao; Yajuan Li; Zheng-Rong Lu
Journal:  ACS Med Chem Lett       Date:  2018-06-06       Impact factor: 4.345

3.  Association of p53 and p21 polymorphisms with prostate cancer.

Authors:  Monika Kmeťová Sivoňová; Marta Vilčková; Ján Kliment; Silvia Mahmood; Jana Jurečeková; Svetlana Dušenková; Iveta Waczulíková; Peter Slezák; Dušan Dobrota
Journal:  Biomed Rep       Date:  2015-07-27

4.  Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans.

Authors:  Bradford D Wilson; Luisel J Ricks-Santi; Tshela E Mason; Muneer Abbas; Rick A Kittles; Georgia M Dunston; Yasmine M Kanaan
Journal:  Cancer Genomics Proteomics       Date:  2018 May-Jun       Impact factor: 4.069

5.  Prostate-specific antigen and perfluoroalkyl acids in the C8 health study population.

Authors:  Alan Ducatman; Jianjun Zhang; Hongmin Fan
Journal:  J Occup Environ Med       Date:  2015-01       Impact factor: 2.162

Review 6.  Mast cells as a potential prognostic marker in prostate cancer.

Authors:  Gianluigi Taverna; Guido Giusti; Mauro Seveso; Rodolfo Hurle; Piergiuseppe Colombo; Sanja Stifter; Fabio Grizzi
Journal:  Dis Markers       Date:  2013-11-11       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.